Literature DB >> 10575098

Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats.

S Zalcman1, I Savina, R A Wise.   

Abstract

Interleukin (IL)-6 mediates brain-immune interactions, influences the survival of postnatal mesencephalic and basal forebrain cells, influences mesocorticolimbic dopamine and serotonin neurotransmission, and is linked with various central nervous system disorders. In the present study, single injections of IL-6 (1 or 2 microg/Long-Evans rat, i.p.) induced modest elevations of locomotor activity. The locomotor increases were not augmented by repeated intermittent injections of IL-6 (five daily injections; 1 microg/rat), however. Nonetheless, repeated IL-6 treatment increased sensitivity to the locomotor-stimulating effects of 1.0 and 0.5 mg/kg amphetamine, when tested 5, 7, or 14 days following interruption of the cytokine treatment. The ability of acute IL-6 injections to alter locomotor activity and the ability of repeated IL-6 injections to produce long-lasting sensitization to the locomotor-stimulating effects of amphetamine suggest an interaction of this cytokine with the mesolimbic dopamine system, a system implicated in aspects of schizophrenia, addiction, and movement disorders. The fact that IL-6 caused a lasting change in responsiveness to amphetamine implies a mechanism by which immunogenic stimuli can alter brain circuitry, changing its sensitivity to seemingly unrelated subsequent stimuli or events.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10575098     DOI: 10.1016/s0006-8993(99)02063-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

Review 1.  Chronic fatigue syndrome: the need for subtypes.

Authors:  Leonard A Jason; Karina Corradi; Susan Torres-Harding; Renee R Taylor; Caroline King
Journal:  Neuropsychol Rev       Date:  2005-03       Impact factor: 7.444

2.  Dual role of PPAR-γ in induction and expression of behavioral sensitization to cannabinoid receptor agonist WIN55,212-2.

Authors:  Leili Enayatfard; Farzaneh Rostami; Sanaz Nasoohi; Shahrbanoo Oryan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Neuromolecular Med       Date:  2013-06-21       Impact factor: 3.843

Review 3.  Inflammation and schizophrenia.

Authors:  Brian Kirkpatrick; Brian J Miller
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

Review 4.  The cytokine model of schizophrenia: emerging therapeutic strategies.

Authors:  Ragy R Girgis; Samhita S Kumar; Alan S Brown
Journal:  Biol Psychiatry       Date:  2013-12-11       Impact factor: 13.382

5.  Neonatal exposure to lipopolysaccharide enhances methamphetamine-induced reinstated behavioral sensitization in adult rats.

Authors:  Lu-Tai Tien; Zhengwei Cai; Philip G Rhodes; Lir-Wan Fan
Journal:  Behav Brain Res       Date:  2011-06-06       Impact factor: 3.332

6.  Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

7.  Kindling and Oxidative Stress as Contributors to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  L A Jason; N Porter; J Herrington; M Sorenson; S Kubow
Journal:  J Behav Neurosci Res       Date:  2009-01-01

8.  The impact of energy modulation on physical functioning and fatigue severity among patients with ME/CFS.

Authors:  Leonard Jason; Mary Benton; Susan Torres-Harding; Kathleen Muldowney
Journal:  Patient Educ Couns       Date:  2009-04-08

Review 9.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

Review 10.  Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Neuropsychopharmacology       Date:  2016-09-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.